Actively Recruiting
Evaluating How Kidney Impairment Affects Ribupatide Levels in Adults With Severe Renal Disease or Healthy Participants Using Weekly Injections
Led by Kailera · Updated on 2026-10-01
32
Participants Needed
2
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the pharmacokinetics of ribupatide in adults with severe kidney problems, including end-stage kidney disease, compared to adults with normal kidney function. The study is designed as a Phase 1, open-label trial to understand how kidney impairment affects the bodys processing of ribupatide after a single dose. It includes healthy participants as well as those with renal impairment, obesity, or overweight conditions. Participants will receive ribupatide as a subcutaneous injection once weekly. The study focuses on measuring the maximum concentration of the drug in plasma and the area under the concentration-time curve up to the last measurable concentration and extrapolated to infinity, over a period extending to 816 hours after dosing on Day 35. This helps estimate how ribupatide behaves in the body depending on kidney function. During the study, participants will have blood samples taken to assess drug levels and will be monitored for any treatment-emergent or serious adverse events from Day 1 up to Day 35. Pregnancy tests and suitability for blood sampling are required at screening. The total participation period includes dosing and follow-up assessments to monitor safety and drug processing, with the study concluding on Day 35.
CONDITIONS
Brief Title
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
Research Team
K
Kailera Therapeutics, Inc.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here